Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Drugs to Prevent Bronchopulmonary Dysplasia: Effect of Baseline Risk on the Number Needed to Treat.

Jensen EA, Roberts RS, Schmidt B.

J Pediatr. 2020 Mar 3. pii: S0022-3476(20)30143-8. doi: 10.1016/j.jpeds.2020.01.070. [Epub ahead of print]

PMID:
32143932
2.

Nasal Intermittent Positive Pressure Ventilation Versus Nasal Continuous Positive Airway Pressure to Prevent Primary Noninvasive Ventilation Failure in Extremely Low Birthweight Infants.

Bourque SL, Roberts RS, Wright CJ, Kirpalani H, Lemyre B, Millar D, Bamat NA.

J Pediatr. 2020 Jan;216:218-221.e1. doi: 10.1016/j.jpeds.2019.08.064. Epub 2019 Oct 8.

PMID:
31604630
3.

Randomized phase 2 trial comparing JNJ-9375, a thrombin-directed antibody, with apixaban for prevention of venous thrombosis.

Weitz JI, Segers A, Raskob G, Roberts RS, Francis C, Lassen MR, Fuji T, Swaim RM, Lee M, Peters G, DiBattiste PM, Tesfaye F, Strony J.

J Thromb Haemost. 2019 Dec;17(12):2081-2088. doi: 10.1111/jth.14639. Epub 2019 Oct 13.

PMID:
31529590
4.

Self-reported Quality of Life at Middle School Age in Survivors of Very Preterm Birth: Results From the Caffeine for Apnea of Prematurity Trial.

Schmidt B, Anderson PJ, Asztalos EV, Doyle LW, Grunau RE, Moddemann D, Roberts RS.

JAMA Pediatr. 2019 May 1;173(5):487-489. doi: 10.1001/jamapediatrics.2018.4853. No abstract available.

5.

Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration.

Askie LM, Darlow BA, Finer N, Schmidt B, Stenson B, Tarnow-Mordi W, Davis PG, Carlo WA, Brocklehurst P, Davies LC, Das A, Rich W, Gantz MG, Roberts RS, Whyte RK, Costantini L, Poets C, Asztalos E, Battin M, Halliday HL, Marlow N, Tin W, King A, Juszczak E, Morley CJ, Doyle LW, Gebski V, Hunter KE, Simes RJ; Neonatal Oxygenation Prospective Meta-analysis (NeOProM) Collaboration.

JAMA. 2018 Jun 5;319(21):2190-2201. doi: 10.1001/jama.2018.5725. Erratum in: JAMA. 2018 Jul 17;320(3):308.

6.

Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity.

Mürner-Lavanchy IM, Doyle LW, Schmidt B, Roberts RS, Asztalos EV, Costantini L, Davis PG, Dewey D, D'Ilario J, Grunau RE, Moddemann D, Nelson H, Ohlsson A, Solimano A, Tin W, Anderson PJ; Caffeine for Apnea of Prematurity (CAP) Trial Group.

Pediatrics. 2018 May;141(5). pii: e20174047. doi: 10.1542/peds.2017-4047. Epub 2018 Apr 11.

7.

4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships.

Roberts RS, Sevilla S, Ferrer M, Taltavull J, Hernández B, Segarra V, Gràcia J, Lehner MD, Gavaldà A, Andrés M, Cabedo J, Vilella D, Eichhorn P, Calama E, Carcasona C, Miralpeix M.

J Med Chem. 2018 Mar 22;61(6):2472-2489. doi: 10.1021/acs.jmedchem.7b01751. Epub 2018 Mar 13.

PMID:
29502405
8.

Variation in Positive End-Expiratory Pressure Levels for Mechanically Ventilated Extremely Low Birth Weight Infants.

Bamat NA, Guevara JP, Bryan M, Roberts RS, Yoder BA, Lemyre B, Chiu A, Millar D, Kirpalani H.

J Pediatr. 2018 Mar;194:28-33.e5. doi: 10.1016/j.jpeds.2017.10.065. Epub 2017 Dec 22.

9.

Effect of Prophylactic Indomethacin in Extremely Low Birth Weight Infants Based on the Predicted Risk of Severe Intraventricular Hemorrhage.

Foglia EE, Roberts RS, Stoller JZ, Davis PG, Haslam R, Schmidt B; Trial of Indomethacin Prophylaxis in Preterms Investigators.

Neonatology. 2018;113(2):183-186. doi: 10.1159/000485172. Epub 2017 Dec 20.

10.

Engaging medical students in problem-based search and study of the biomedical literature.

Han Z, Margulies SL, Kurian D, Jabaut JM, Mehta A, Dudum R, Koudoro H, Roberts RS, Lee J, Li J, Nguyen HT, Elliott M.

Int J Med Educ. 2017 Aug 17;8:297-299. doi: 10.5116/ijme.5975.c0bc. No abstract available.

11.

Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.

Schmidt B, Roberts RS, Anderson PJ, Asztalos EV, Costantini L, Davis PG, Dewey D, D'Ilario J, Doyle LW, Grunau RE, Moddemann D, Nelson H, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity (CAP) Trial Group.

JAMA Pediatr. 2017 Jun 1;171(6):564-572. doi: 10.1001/jamapediatrics.2017.0238.

PMID:
28437520
12.

Noninvasive FFR Derived From Coronary CT Angiography: Management and Outcomes in the PROMISE Trial.

Lu MT, Ferencik M, Roberts RS, Lee KL, Ivanov A, Adami E, Mark DB, Jaffer FA, Leipsic JA, Douglas PS, Hoffmann U.

JACC Cardiovasc Imaging. 2017 Nov;10(11):1350-1358. doi: 10.1016/j.jcmg.2016.11.024. Epub 2017 Apr 12.

13.

Oxygen Targeting in Infants Born Extremely Preterm Who Are Small for Gestational Age: A Need for Heightened Vigilance.

Schmidt B, Whyte RK, Roberts RS.

J Pediatr. 2017 Jul;186:9-10. doi: 10.1016/j.jpeds.2017.02.071. Epub 2017 Mar 18. No abstract available.

PMID:
28318530
14.

Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing: The PROMISE Minimal-Risk Tool, A Secondary Analysis of a Randomized Clinical Trial.

Fordyce CB, Douglas PS, Roberts RS, Hoffmann U, Al-Khalidi HR, Patel MR, Granger CB, Kostis J, Mark DB, Lee KL, Udelson JE; Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) Investigators.

JAMA Cardiol. 2017 Apr 1;2(4):400-408. doi: 10.1001/jamacardio.2016.5501. Erratum in: JAMA Cardiol. 2018 Dec 1;3(12):1256.

15.

Perceived Stress in Patients with Common Gastrointestinal Disorders: Associations with Quality of Life, Symptoms and Disease Management.

Edman JS, Greeson JM, Roberts RS, Kaufman AB, Abrams DI, Dolor RJ, Wolever RQ.

Explore (NY). 2017 Mar - Apr;13(2):124-128. doi: 10.1016/j.explore.2016.12.005. Epub 2016 Dec 16.

16.

Benefits of Oxygen Saturation Targeting Trials: Oximeter Calibration Software Revision and Infant Saturations.

Whyte RK, Nelson H, Roberts RS, Schmidt B.

J Pediatr. 2017 Mar;182:382-384. doi: 10.1016/j.jpeds.2016.11.076. Epub 2017 Jan 12. Review.

PMID:
28088392
17.

Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.

Gràcia J, Buil MA, Castro J, Eichhorn P, Ferrer M, Gavaldà A, Hernández B, Segarra V, Lehner MD, Moreno I, Pagès L, Roberts RS, Serrat J, Sevilla S, Taltavull J, Andrés M, Cabedo J, Vilella D, Calama E, Carcasona C, Miralpeix M.

J Med Chem. 2016 Dec 8;59(23):10479-10497. Epub 2016 Nov 17.

PMID:
27933955
18.

Effects of Targeting Higher or Lower Oxygen Saturations in Centers with More Versus Less Separation between Median Saturations.

Schmidt B, Whyte RK, Shah PS, Abbasi S, Bairam A, Harrold J, Roberts RS; Canadian Oxygen Trial (COT) Group.

J Pediatr. 2016 Nov;178:288-291.e2. doi: 10.1016/j.jpeds.2016.08.002. Epub 2016 Sep 2.

PMID:
27597731
19.

Prospective economic evaluation alongside the non-invasive ventilation trial.

Mowitz ME, Zupancic JA, Millar D, Kirpalani H, Gaulton JS, Roberts RS, Mao W, Dukhovny D.

J Perinatol. 2017 Jan;37(1):61-66. doi: 10.1038/jp.2016.159. Epub 2016 Sep 29.

20.

Tonsillectomy Bleed Rates across the CHEER Practice Research Network: Pursuing Guideline Adherence and Quality Improvement.

Lee WT, Witsell DL, Parham K, Shin JJ, Chapurin N, Pynnonen MA, Langman A, Nguyen-Huynh A, Ryan SE, Vambutas A, Roberts RS, Schulz K.

Otolaryngol Head Neck Surg. 2016 Jul;155(1):28-32. doi: 10.1177/0194599816630523.

21.

Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of sulphone-based CRTh2 antagonists.

Buil MA, Calbet M, Castillo M, Castro J, Esteve C, Ferrer M, Forns P, González J, López S, Roberts RS, Sevilla S, Vidal B, Vidal L, Vilaseca P.

Eur J Med Chem. 2016 May 4;113:102-33. doi: 10.1016/j.ejmech.2016.02.023. Epub 2016 Feb 11.

PMID:
26922232
22.

Prediction of Late Death or Disability at Age 5 Years Using a Count of 3 Neonatal Morbidities in Very Low Birth Weight Infants.

Schmidt B, Roberts RS, Davis PG, Doyle LW, Asztalos EV, Opie G, Bairam A, Solimano A, Arnon S, Sauve RS; Caffeine for Apnea of Prematurity (CAP) Trial Investigators; Caffeine for Apnea of Prematurity CAP Trial Investigators.

J Pediatr. 2015 Nov;167(5):982-6.e2. doi: 10.1016/j.jpeds.2015.07.067. Epub 2015 Aug 28.

PMID:
26318030
23.

Association Between Intermittent Hypoxemia or Bradycardia and Late Death or Disability in Extremely Preterm Infants.

Poets CF, Roberts RS, Schmidt B, Whyte RK, Asztalos EV, Bader D, Bairam A, Moddemann D, Peliowski A, Rabi Y, Solimano A, Nelson H; Canadian Oxygen Trial Investigators.

JAMA. 2015 Aug 11;314(6):595-603. doi: 10.1001/jama.2015.8841.

PMID:
26262797
24.

A comparison of bilevel and ventilator-delivered non-invasive respiratory support.

Millar D, Lemyre B, Kirpalani H, Chiu A, Yoder BA, Roberts RS.

Arch Dis Child Fetal Neonatal Ed. 2016 Jan;101(1):F21-5. doi: 10.1136/archdischild-2014-308123. Epub 2015 Jul 10.

PMID:
26162889
25.

Integrative Medicine Patients Have High Stress, Pain, and Psychological Symptoms.

Wolever RQ, Goel NS, Roberts RS, Caldwell K, Kligler B, Dusek JA, Perlman A, Dolor R, Abrams DI.

Explore (NY). 2015 Jul-Aug;11(4):296-303. doi: 10.1016/j.explore.2015.04.003. Epub 2015 Apr 30.

PMID:
26044918
26.

Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.

Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE Jr, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ; IPFnet investigators.

Lancet Respir Med. 2015 May;3(5):388-96. doi: 10.1016/S2213-2600(15)00093-4. Epub 2015 Apr 15.

27.

Social variables predict gains in cognitive scores across the preschool years in children with birth weights 500 to 1250 grams.

Manley BJ, Roberts RS, Doyle LW, Schmidt B, Anderson PJ, Barrington KJ, Böhm B, Golan A, van Wassenaer-Leemhuis AG, Davis PG; Caffeine for Apnea of Prematurity (CAP) Trial Investigators; Caffeine for Apnea of Prematurity CAP Trial Investigators.

J Pediatr. 2015 Apr;166(4):870-6.e1-2. doi: 10.1016/j.jpeds.2014.12.016. Epub 2015 Jan 29.

PMID:
25641237
28.

Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists III: the role of a hydrogen-bond acceptor in long receptor residence times.

Alonso JA, Andrés M, Bravo M, Buil MA, Calbet M, Castro J, Eastwood PR, Esteve C, Ferrer M, Forns P, Gómez E, González J, Lozoya E, Mir M, Moreno I, Petit S, Roberts RS, Sevilla S, Vidal B, Vidal L, Vilaseca P.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):5127-33. doi: 10.1016/j.bmcl.2014.08.028. Epub 2014 Aug 19.

PMID:
25437506
29.

Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists II: lead optimization.

Alonso JA, Andrés M, Bravo M, Calbet M, Eastwood PR, Eichhorn P, Esteve C, Ferrer M, Gómez E, González J, Mir M, Moreno I, Petit S, Roberts RS, Sevilla S, Vidal B, Vidal L, Vilaseca P, Zanuy M.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):5123-6. doi: 10.1016/j.bmcl.2014.08.029. Epub 2014 Aug 19.

PMID:
25437505
30.

Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of bicyclic heteroaromatic acetic acids as potent CRTh2 antagonists I.

Alonso JA, Andrés M, Bravo M, Buil MA, Calbet M, Castro J, Eastwood PR, Eichhorn P, Esteve C, Gómez E, González J, Mir M, Petit S, Roberts RS, Vidal B, Vidal L, Vilaseca P, Zanuy M.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):5118-22. doi: 10.1016/j.bmcl.2014.09.005. Epub 2014 Oct 15.

PMID:
25437504
31.

Structure-activity relationships (SAR) and structure-kinetic relationships (SKR) of pyrrolopiperidinone acetic acids as CRTh2 antagonists.

Andrés M, Buil MA, Calbet M, Casado O, Castro J, Eastwood PR, Eichhorn P, Ferrer M, Forns P, Moreno I, Petit S, Roberts RS.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):5111-7. doi: 10.1016/j.bmcl.2014.08.026. Epub 2014 Aug 18.

PMID:
25437503
32.

Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age.

Marcus CL, Meltzer LJ, Roberts RS, Traylor J, Dix J, D'ilario J, Asztalos E, Opie G, Doyle LW, Biggs SN, Nixon GM, Narang I, Bhattacharjee R, Davey M, Horne RS, Cheshire M, Gibbons J, Costantini L, Bradford R, Schmidt B; Caffeine for Apnea of Prematurity–Sleep Study.

Am J Respir Crit Care Med. 2014 Oct 1;190(7):791-9. doi: 10.1164/rccm.201406-1092OC.

33.

Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis.

Collard HR, Brown KK, Martinez FJ, Raghu G, Roberts RS, Anstrom KJ.

Chest. 2014 Nov;146(5):1256-1262. doi: 10.1378/chest.14-0492.

34.

Feasibility of comprehensive, unattended ambulatory polysomnography in school-aged children.

Marcus CL, Traylor J, Biggs SN, Roberts RS, Nixon GM, Narang I, Bhattacharjee R, Davey MJ, Horne RS, Cheshire M, Gibbons KJ, Dix J, Asztalos E, Doyle LW, Opie GF, D'ilario J, Costantini L, Bradford R, Schmidt B.

J Clin Sleep Med. 2014 Aug 15;10(8):913-8. doi: 10.5664/jcsm.3970.

35.

Impact of study oximeter masking algorithm on titration of oxygen therapy in the Canadian oxygen trial.

Schmidt B, Roberts RS, Whyte RK, Asztalos EV, Poets C, Rabi Y, Solimano A, Nelson H; Canadian Oxygen Trial Group.

J Pediatr. 2014 Oct;165(4):666-71.e2. doi: 10.1016/j.jpeds.2014.05.028. Epub 2014 Jun 25.

PMID:
24973289
36.

Characteristics of cancer patients presenting to an integrative medicine practice-based research network.

Edman JS, Roberts RS, Dusek JA, Dolor R, Wolever RQ, Abrams DI.

Integr Cancer Ther. 2014 Sep;13(5):405-10. doi: 10.1177/1534735414537876. Epub 2014 Jun 9.

PMID:
24913179
37.

Trade-off between lower or higher oxygen saturations for extremely preterm infants: the first benefits of oxygen saturation targeting (BOOST) II trial reports its primary outcome.

Schmidt B, Whyte RK, Roberts RS.

J Pediatr. 2014 Jul;165(1):6-8. doi: 10.1016/j.jpeds.2014.03.004. Epub 2014 Apr 14. No abstract available.

PMID:
24726542
38.

Timing of caffeine therapy in very low birth weight infants.

Schmidt B, Davis PG, Roberts RS.

J Pediatr. 2014 May;164(5):957-8. doi: 10.1016/j.jpeds.2014.01.054. Epub 2014 Mar 12. No abstract available.

PMID:
24630349
39.

Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits.

Yau JW, Liao P, Fredenburgh JC, Roberts RS, Weitz JI.

Thromb Haemost. 2014 Jul 3;112(1):79-86. doi: 10.1160/TH13-12-1047. Epub 2014 Feb 27.

PMID:
24573541
40.

Association between severe retinopathy of prematurity and nonvisual disabilities at age 5 years.

Schmidt B, Davis PG, Asztalos EV, Solimano A, Roberts RS.

JAMA. 2014 Feb 5;311(5):523-5. doi: 10.1001/jama.2013.282153. No abstract available.

PMID:
24496539
41.

Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.

Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G; IPFnet Investigators.

Lancet Respir Med. 2013 Jul;1(5):369-76. doi: 10.1016/S2213-2600(13)70105-X. Epub 2013 Jun 14.

42.

2-(1H-Pyrazol-1-yl)acetic acids as chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes (CRTh2) antagonists.

Andrés M, Bravo M, Buil MA, Calbet M, Castillo M, Castro J, Eichhorn P, Ferrer M, Lehner MD, Moreno I, Roberts RS, Sevilla S.

Eur J Med Chem. 2014 Jan;71:168-84. doi: 10.1016/j.ejmech.2013.10.072. Epub 2013 Nov 9.

PMID:
24292338
43.

Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.

Majeed A, Meijer K, Larrazabal R, Arnberg F, Luijckx GJ, Roberts RS, Schulman S.

Thromb Haemost. 2014 Feb;111(2):233-9. doi: 10.1160/TH13-07-0536. Epub 2013 Oct 24.

PMID:
24154891
44.

A trial comparing noninvasive ventilation strategies in preterm infants.

Kirpalani H, Millar D, Lemyre B, Yoder BA, Chiu A, Roberts RS; NIPPV Study Group.

N Engl J Med. 2013 Aug 15;369(7):611-20. doi: 10.1056/NEJMoa1214533.

45.

Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial.

Schmidt B, Whyte RK, Asztalos EV, Moddemann D, Poets C, Rabi Y, Solimano A, Roberts RS; Canadian Oxygen Trial (COT) Group.

JAMA. 2013 May 22;309(20):2111-20. doi: 10.1001/jama.2013.5555.

PMID:
23644995
46.

Phosphodiesterase-4 inhibitors: a review of current developments (2010 - 2012).

Gavaldà A, Roberts RS.

Expert Opin Ther Pat. 2013 Aug;23(8):997-1016. doi: 10.1517/13543776.2013.794789. Epub 2013 May 4. Review.

PMID:
23642007
47.

2-(1H-Pyrazol-4-yl)acetic acids as CRTh2 antagonists.

Andrés M, Bravo M, Buil MA, Calbet M, Castro J, Domènech T, Eichhorn P, Ferrer M, Gómez E, Lehner MD, Moreno I, Roberts RS, Sevilla S.

Bioorg Med Chem Lett. 2013 Jun 1;23(11):3349-53. doi: 10.1016/j.bmcl.2013.03.093. Epub 2013 Apr 2.

PMID:
23601708
48.

By increasing the affinity of heparin for fibrin, Zn(2+) promotes the formation of a ternary heparin-thrombin-fibrin complex that protects thrombin from inhibition by antithrombin.

Chan HH, Leslie BA, Stafford AR, Roberts RS, Al-Aswad NN, Fredenburgh JC, Weitz JI.

Biochemistry. 2012 Oct 9;51(40):7964-73. doi: 10.1021/bi301046b. Epub 2012 Sep 28.

PMID:
22978548
49.

Spiroindolines identify the vesicular acetylcholine transporter as a novel target for insecticide action.

Sluder A, Shah S, Cassayre J, Clover R, Maienfisch P, Molleyres LP, Hirst EA, Flemming AJ, Shi M, Cutler P, Stanger C, Roberts RS, Hughes DJ, Flury T, Robinson MP, Hillesheim E, Pitterna T, Cederbaum F, Worthington PA, Crossthwaite AJ, Windass JD, Currie RA, Earley FG.

PLoS One. 2012;7(5):e34712. doi: 10.1371/journal.pone.0034712. Epub 2012 May 1.

50.

Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.

Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos EV, Davis PG, Tin W, Moddemann D, Solimano A, Ohlsson A, Barrington KJ, Roberts RS; Caffeine for Apnea of Prematurity (CAP) Trial Investigators.

JAMA. 2012 Jan 18;307(3):275-82. doi: 10.1001/jama.2011.2024.

PMID:
22253394

Supplemental Content

Loading ...
Support Center